DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Capivasertib is an investigational drug.
There have been 19 clinical trials for Capivasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 25th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are one hundred and forty-nine US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Capivasertib
|A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours||AstraZeneca||Phase 1|
|Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma||Parexel||Phase 2|
|Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma||AstraZeneca||Phase 2|
Top disease conditions for Capivasertib
Top clinical trial sponsors for Capivasertib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Capivasertib||⤷ Try it Free||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||Polymeric nanoparticles and methods of making and using same||Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide||AstraZeneca AB (Sodertalje, SE)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy||Oncoceutics, Inc. (Philadelphia, PA)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||Heterocyclic estrogen receptor modulators and uses thereof||Genentech, Inc. (South San Francisco, CA)||⤷ Try it Free|
|Capivasertib||⤷ Try it Free||Protein kinase B inhibitors||AstraZeneca AB (Sodertalje, SE)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Capivasertib||Australia||AU2015244171||2034-04-11||⤷ Try it Free|
|Capivasertib||Australia||AU2015244179||2034-04-11||⤷ Try it Free|
|Capivasertib||Canada||CA2945128||2034-04-11||⤷ Try it Free|
|Capivasertib||Canada||CA2945129||2034-04-11||⤷ Try it Free|
|Capivasertib||China||CN106414451||2034-04-11||⤷ Try it Free|
|Capivasertib||China||CN106459063||2034-04-11||⤷ Try it Free|
|Capivasertib||European Patent Office||EP3129377||2034-04-11||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|